Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

  • Who We Are
    • About
    • Mission
    • History
    • Divisions
      • Atlanta
        • Atlanta Leadership
        • Atlanta Contacts
      • Caribbean
        • Caribbean Leadership
        • Caribbean Contacts
      • Chicago
        • Chicago Leadership
        • Chicago Contacts
      • Dallas
        • Dallas Leadership
        • Dallas Contacts
      • Detroit
        • Detroit Leadership
        • Detroit Contacts
      • El Paso
        • El Paso Leadership
        • El Paso Contacts
      • Headquarters
      • Houston
        • Houston Leadership
        • Houston Contacts
      • Los Angeles
        • Los Angeles Leadership
        • Los Angeles Contacts
      • Louisville
        • Louisville Leadership
        • Louisville Contacts
      • Miami
        • Miami Leadership
        • Miami Contacts
      • New England
        • New England Leadership
        • New England Contacts
      • New Jersey
        • New Jersey Contacts
      • New Orleans
        • New Orleans Leadership
        • New Orleans Contacts
      • New York
        • New York Leadership
        • New York Contacts
      • Omaha
        • Omaha Leadership
        • Omaha Contacts
      • Philadelphia
        • Philadelphia Leadership
        • Philadelphia Contacts
      • Phoenix
        • Phoenix Leadership
        • Phoenix Contacts
      • Rocky Mountain
        • Rocky Mountain Contacts
      • San Diego
        • San Diego Leadership
        • San Diego Contacts
      • San Francisco
        • San Francisco Contacts
      • Seattle
        • Seattle Contacts
      • St. Louis
        • St. Louis Leadership
        • St. Louis Contacts
      • Washington, DC
        • Washington Leadership
        • Washington Contacts
    • DEA Museum
    • Foreign Offices
      • Africa
      • Andean
      • Caribbean
      • Europe
      • Far East
      • Middle East
      • North and Central America
      • Southern Cone
    • Operational Divisions
      • Aviation Division
      • Diversion Control Division
    • Wall of Honor
    • Contact Us
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • What We Do
    • Law Enforcement
      • DEA Office of Training
        • Office of Training Programs
      • El Paso Intelligence Center (EPIC)
        • Leadership
        • Mission
        • Services
        • Contacts
      • Forensic Sciences
        • Computer Forensics Program
        • Environmental Management
        • Laboratories
      • Intelligence
      • Operations
        • Administrative Law Judges
        • DEA Asset Forfeiture
        • Domestic Cannabis Suppression / Eradication Program
        • HIDTA
        • OCDETF
        • State and Local Task Forces
    • Education and Prevention
      • DEA’s Family Summit
      • Operation Engage
      • Community Outreach
      • Red Ribbon
        • Kiki and the History of Red Ribbon Week
        • Red Ribbon Toolkit - Resources For Your Community
      • Just Think Twice
      • Campus Drug Prevention
      • Get Smart About Drugs
      • Operation Prevention
    • Drug Information
      • Drug Policy
      • Drug Scheduling
      • The Controlled Substances Act
    • News
      • Alerts
      • Press Releases
      • Most Wanted Fugitives
        • All Fugitives
      • Stories
      • Events
      • Speeches
      • Testimony
    • Campaigns
      • One Pill Can Kill
        • Partner Toolbox
        • Social Media Campaign
      • DEA National Prescription Drug Take Back Day
  • Careers
    • Special Agent
      • Special Agent FAQs
      • Special Agent Job Announcements
    • Diversion Investigator
      • Diversion Investigator Job Announcement
    • Intelligence Research Specialist
      • Intelligence Research Specialist Job Announcements
      • Intelligence Research Specialists FAQs
      • Schedule A Hiring Authority: Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • How to Apply
      • Employment Requirements
      • Equal Opportunity Employer
      • How To Claim Veterans' Preference
      • Priority Consideration
      • Benefits
      • Veterans and People With Disabilities
  • Resources
    • Recovery Resources
    • Data and Statistics
      • Domestic Arrests
      • Staffing and Budget
    • FOIA
      • About FOIA
      • Contact DEA FOIA
      • Make a Request
      • What Happens After Making a Request
      • Requester Categories
      • Fees Charged
      • Fee Waiver
      • FOIA FAQ
      • FOIA Logs and Reports
      • FOIA Library
      • Additional FOIA Links
      • FOIA Exemptions
      • What Are Exclusions?
      • Privacy Act
      • Privacy Act Exemptions
      • Privacy Impact Assessment and Management Information Systems
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
      • Victim Witness Assistance Program Resources

United States Drug Enforcement Administration

  • Search
  • Full Menu

Main Menu

  • Who We Are
  • What We Do
  • Careers
  • Resources
  • Submit A Tip
  • Get Updates
  • Scam Alert
  • English
  • ES

PUBLIC SAFETY ALERT

DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine - DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine

Drug Enforcement Administration

Shelly S. Howe Special Agent in Charge
San Diego
@DEASanDiegoDiv
September 02, 2021
Contact: Kelly McKay
Phone Number: (571) 324-6204
For Immediate Release

San Diego Doctor Pays $200,000 to Resolve Allegations that He Wrote Illegitimate Opioid Prescriptions

SAN DIEGO – San Diego area pain clinic doctor Brenton Wynn, M.D., has paid $200,000 to resolve allegations that he illegally prescribed opioids and other dangerous drugs to his patients, according to a settlement agreement signed by Dr. Wynn and the United States.  The settlement stems from the United States’ continued efforts to combat the opioid epidemic on all fronts, including this investigation of whether Dr. Wynn illegally prescribed opioids to his patients in violation of the Controlled Substances Act.

The Controlled Substances Act provides that doctors may write prescriptions for opioids only for a legitimate medical purpose while acting in the usual course of their professional practice. The United States alleged that Dr. Wynn wrote opioid prescriptions to patients without a legitimate medical purpose and/or outside the usual course of his professional practice for more than five years.  Dr. Wynn wrote prescriptions for fentanyl, oxycodone, hydromorphone, methadone, oxymorphone, and morphine. 

The United States further alleged that Dr. Wynn prescribed at the same time a dangerous combination of opioids and benzodiazepines such as Xanax and Valium.  Of even more concern, Dr. Wynn allegedly prescribed to some patients a combination of at least one opioid, one benzodiazepine and one muscle relaxant such as Soma.  Drug abusers colloquially refer to the opioid, benzodiazepine, and muscle relaxant combination as the “Trinity” or “Holy Trinity” because of its rapid euphoric effects.  These drug combinations are known to significantly increase the risk of addiction, abuse, and overdose.

The investigation exemplifies the Department of Justice’s willingness to investigate doctors who may be overprescribing opioids while treating patients who suffer painful conditions.  Such doctors must still only prescribe opioids in accordance with recognized and accepted medical standards.  Indeed, public health experts have long warned health care providers that overdose risk is elevated in patients receiving medically prescribed opioids, particularly those receiving high dosages.  Doctors and other health care providers should carefully track the potency of opioids prescribed to patients by noting the Morphine Milligram Equivalent (MME, also commonly referred to as Morphine Equivalent Dose or MED) of prescribed opioids.  Among other things, tracking MMEs advances better practices for pain management by reinforcing the need for providers to consider alternatives to using high-dosage opioids to treat pain and to appropriately justify decisions to use opioids at dosages that place patients at high risk of addiction, abuse, and overdose.  Furthermore, prescribing high dosages increases the risk that patients will divert opioids.

Based on its investigation, the United States alleged that Dr. Wynn prescribed large quantities of opioids to his patients that reached high daily MME levels, often even exceeding 120 MME.  The United States further alleged that Dr. Wynn sometimes continued to prescribe dangerous opioids even when his patients’ urine drug test results showed that they were not taking the drugs Dr. Wynn prescribed. 

“While the vast amount of medical professionals prescribe opioids legitimately and are meeting their patients’ standard of care, DEA will vigorously pursue information from the public about the doctors who are not,” said DEA Special Agent in Charge John W. Callery. “DEA will always protect the public from doctors who put their patients in harm’s way.”

The DEA has a pending administrative action against Dr. Wynn (Docket No. 20-10) to revoke his ability to prescribe opioids and other controlled substances.

“Even in our climate of heightened awareness of the dangers of opioids, some doctors continue to overprescribe opioids,” said Acting U.S. Attorney Randy Grossman.  “This office will pursue those overprescribing doctors and bring them to justice.  And as we have consistently demonstrated, we will continue to use all available tools to combat the serious opioid epidemic.” Grossman commended Assistant U.S. Attorney Dylan Aste and the Drug Enforcement Administration for their work on the investigation.

To report a tip directly to a DEA representative regarding medical personnel writing suspicious opioid prescriptions and pharmacies dispensing large amounts of opioids, call (571) 324-6499, or visit the DEA’s website (https://www.deadiversion.usdoj.gov/) and click on “Report Illicit Pharmaceutical Activities.”

AGENCIES:  United States Attorney’s Office

###

SAMHSA Behavioral Health Treatment Locator

  • Who We Are
    • About
    • Domestic Divisions
    • Foreign Offices
    • Contact Us
    • DEA Museum
  • What We Do
    • Drug Prevention
    • Law Enforcement
    • Diversion Control Division
    • News
  • Careers
    • Overview
    • Special Agent
    • Diversion Investigator
    • Intelligence Research Specialist
  • Resources
    • Drug Information
    • Employee Assistance Program
    • Equal Opportunity Employer
    • FOIA
    • Publications
    • Media Galleries
    • VWAP
  • Doing Business
    with the DEA
    • Overview
    • Current Vendors
    • Prospective Vendors
    • Security Clauses
    • Security Forms
    • Small Business Program
  • Policies
    • Accessibility, Plug-ins & Policy
    • Legal Policies & Disclaimers
    • No FEAR Act
    • Privacy Policy
    • U.S. Department of Justice EEO Policy
    • USA.gov
    • Whistleblower Protection
Home

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook Twitter LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster